CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Velsipity etrasimod Ulcerative colitis Active
Remsima infliximab Crohn’s disease Reimburse with clinical criteria and/or conditions Active
Remsima infliximab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Active
Qulipta atogepant Migraine, prevention Active
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
Vraylar cariprazine Schizophrenia Active
Livmarli maralixibat Alagille syndrome Reimburse with clinical criteria and/or conditions Active
Leqvio inclisiran Primary hypercholesterolemia Do not reimburse Active
TBC avapritinib Advanced Systemic Mastocytosis Active
Keytruda pembrolizumab Gastric or gastroesophageal junction adenocarcinoma Active
Last Updated : May 11, 2024